Evidence map›Paper›PMID 41659881›Full record

ArticleFrontiers in immunology2026

Immunophenotyping TCF1-expressing TILs: spatial profiling and prognostic value in operable non-small cell lung cancer.

Konstantinos Ntostoglou, Georgios Christodoulopoulos, Katie Stoker, Jean Descarpentrie, Anastasia Xagara, Dora Chatzidaki, Vasiliki Anastasopoulou, Ilias P Nikas, Argyro Ioanna Ieronimaki, Lucy Booth and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Konstantinos Ntostoglou *Hellenic Oncology Research Group (HORG), Athens, Greece.
Georgios Christodoulopoulos *Laboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Katie Stoker *St. John's Institute of Dermatology, School of Basic and Medical Biosciences and KHP Centre for Translational Medicine, King's College London, Guy's Hospital, London, United Kingdom.
Jean Descarpentrie *Department of Molecular Biology and Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden.
Anastasia XagaraLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Dora ChatzidakiHellenic Oncology Research Group (HORG), Athens, Greece.
Vasiliki AnastasopoulouHellenic Oncology Research Group (HORG), Athens, Greece.
Ilias P NikasMedical School, University of Cyprus, Nicosia, Cyprus.
Argyro Ioanna Ieronimaki2nd Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Lucy BoothSt. John's Institute of Dermatology, School of Basic and Medical Biosciences and KHP Centre for Translational Medicine, King's College London, Guy's Hospital, London, United Kingdom.
Sophia TsokaDepartment of Informatics, Faculty of Natural, Mathematical and Engineering Sciences, King's College London, London, United Kingdom.
Ioannis VamvakarisDepartment of Pathology, 'Sotiria' General Hospital for Chest Diseases, Athens, Greece.
Apostolos KlinakisHellenic Oncology Research Group (HORG), Athens, Greece.
Eleni PatseaDepartment of Pathology, Metropolitan Hospital, Athens, Greece.
Sophia N KaragiannisSt. John's Institute of Dermatology, School of Basic and Medical Biosciences and KHP Centre for Translational Medicine, King's College London, Guy's Hospital, London, United Kingdom.
Ioannis G Panayiotides2nd Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Teresa FrisanDepartment of Molecular Biology and Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden.
Vassilis GeorgouliasHellenic Oncology Research Group (HORG), Athens, Greece.
Athanasios KotsakisLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Ioannis S Pateras2nd Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The spatial distribution and functional heterogeneity of tumor-infiltrating lymphocytes (TILs) significantly impact patient outcomes in non-small cell lung cancer (NSCLC). While T cell factor 1 (TCF1) expressing TILs have emerged as key players in sustaining anti-tumor immunity, their subset characterization, localization, and clinical significance within the tumor microenvironment remain poorly defined. Method: We performed multiplex immunohistochemistry and immunofluorescence to characterize TCF1 Results: CD4 Conclusions: Our findings support a more refined framework for TCF1

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsLymphocytes, Tumor-InfiltratingT Cell Transcription Factor 1AgedBiomarkers, TumorFemaleHumansImmunophenotypingMaleMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorT Cell Transcription Factor 1biomarkersnon-small cell lung cancerspatial analysisT cell factor 1tumor infiltrating lymphocytestumor microenvironment

Identifiers

PMID41659881
PMCPMC12872492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.